Schedule a Visit
Fill out the form, shoot us an email or give us a call. We are here to answer your questions and schedule your visit.
Send an email:
—Lauren LeBano Ketamine can quickly alleviate symptoms of obsessive-compulsive disorder (OCD) in patients with constant intrusive thoughts, and the drug’s effects can last for one to two weeks in certain patients. Researchers reported these findings in a poster presented at the American Psychiatric Association’s (APA) annual meeting. The rapid symptom relief seen from ketamine is […]
By Tracie White Geuris “Jerry” Rivas, a native of New York, was diagnosed with severe obsessive-compulsive disorder when he was 15. Obsessions with organizing and reorganizing the belongings in his bedroom — posters, comic books, videos — took over most of his life. Forced by germ obsessions to compulsively wash and rewash his hands, he […]
By MEGHANA KESHAVAN @megkesh and DAMIAN GARDE @damiangarde An experimental drug touted as a breakthrough for treating severe postpartum depression is showing some promising results in a small clinical trial. Sage Therapeutics (SAGE), based in Cambridge, Mass., reported on Tuesday that 7 of the 10 women who took the drug in the trial experienced significant improvement in their depression within […]
– Kevin Kunzmann MD Magazine Ketamine infusion, combined with mindfulness-based behavioral changes, has been shown to improve various aspects of treatment outcomes among rehabilitating cocaine-dependent individuals. The new findings from a randomized clinical trial show just a single infusion of the highly potent—yet controversial—NMDA receptor agonist is associated with significant patient improvements in cocaine abstinence at the […]
Abstract Objective: Subanesthetic ketamine doses have been shown to have rapid yet transient antidepressant effects in patients with treatment-resistant depression, which may be prolonged by repeated administration. The purpose of this study was to evaluate the antidepressant effects of a single ketamine infusion, a series of repeated ketamine infusions, and prolongation of response with maintenance […]
-Matt Hoffman The American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists have released consensus guidelines on the use of intravenous (IV) ketamine for the management of acute pain. “The use of ketamine for chronic pain has skyrocketed, and because it is an off-label use of […]
-Isaac V. Cohen, Tigran Makunts, Rabia Atayee & Ruben Abagyan Scientific Reports 7, article number 1450 (2017) Abstract Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence. Here we provide new support for the antidepressant effect of an anesthetic drug, ketamine, by Inverse-Frequency Analysis of eight […]
Ketamine, a medication commonly used for pain relief and increasingly used for depression, may help alleviate migraine pain in patients who have not been helped by other treatments, suggests a study being presented at the ANESTHESIOLOGY® 2017 annual meeting. The study of 61 patients found that almost 75 percent experienced an improvement in their migraine intensity […]
By Tracie White Illustration by Kotryna Zukauskaite Geuris “Jerry” Rivas, a native of New York, was diagnosed with severe obsessive-compulsive disorder when he was 15. Obsessions with organizing and reorganizing the belongings in his bedroom — posters, comic books, videos — took over most of his life. Forced by germ obsessions to compulsively wash and […]
Highlights Preliminary evidence suggests that ketamine may be effective in addiction. Potential interacting mechanisms are enhancing neurogenesis and psychological therapies. Ketamine may reduce depressive symptoms in a risky window for addiction relapse. Abstract Ketamine is a dissociative anaesthetic drug which acts on the central nervous system chiefly through antagonism of the n-methyl-d-aspartate (NMDA) receptor. Recently, ketamine has attracted attention as a rapid-acting anti-depressant but other studies have also […]
The total economic burden of MDD is now estimated to be $210.5 billion per year, representing a 21.5% increase from $173.2 billion per year in 2005. Of particular interest is that nearly half (48%-50%) of these costs are attributed to the workplace, including absenteeism (missed days from work) and presenteeism (reduced productivity while at work), whereas 45%-47% are due to direct medical costs (e.g., outpatient and inpatient medical services, pharmacy costs), which are shared by employers, employees, and society. About 5% of the total expenditures are related to suicide.